Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12170755 | 0.89 | PREP (0.38) | PREPDRD2CA12CA1CA9 | |
| SCHEMBL16768167 | 0.89 | PREP (0.38) | PREPDRD2CA12CA1CA9 | |
| SCHEMBL22263572 | 0.89 | PREP (0.44) | PREPDRD2CA12CA1CA9 | |
| SCHEMBL559379 | 0.84 | DRD2 (0.39) | DRD2CA12CA1CA9PPARA | |
| SCHEMBL2506528 | 0.81 | SRD5A2 (0.46) | PREPCA12CA1CA9POLB | |
| SCHEMBL5281699 | 0.79 | POLB (0.51) | PREPDRD2CA12CA1CA9 | |
| SCHEMBL2507099 | 0.78 | PREP (0.43) | PREPDRD2CA12CA1CA9 | |
| SCHEMBL559283 | 0.77 | HTT (0.54) | POLB | |
| SCHEMBL3839217 | 0.77 | CYP4F2 (0.50) | PREPDRD2 | |
| SCHEMBL12188771 | 0.76 | BLM (0.33) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY | 2024-07-18 | — | — | US | claimed |
| US-11939332-B2 | Synthesis of coelenterazine | INTERNATIONAL PAPER COMPANY (US) | 2024-03-26 | — | — | US | claimed |
| EP-3830088-A1 | SYNTHESIS OF COELENTERAZINE | International Paper Company (US) | 2021-06-09 | — | — | EP | claimed |
| US-20210070762-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY (US) | 2021-03-11 | — | — | US | claimed |
| CN-112368286-A | Synthesis of coelenterazine | 国际纸业公司 | 2021-02-12 | — | — | CN | claimed |
| US-20260016473-A1 | REAGENT FOR DETECTING SARS-RELATED CORONAVIRUS | AIST (JP) | 2026-01-15 | — | — | US | disclosed |
| WO-2025084165-A1 | METHOD FOR EVALUATING DENATURED STATE OF ANTIBODY | 国立研究開発法人産業技術総合研究所 | 2025-04-24 | — | — | WO | disclosed |
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY | 2024-07-18 | — | — | US | disclosed |
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY | 2024-07-18 | — | — | US | disclosed |
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | INTERNATIONAL PAPER COMPANY | 2024-07-18 | — | — | US | disclosed |
| EP-4344689-A2 | SYNTHESIS OF COELENTERAZINE | International Paper Company (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11939332-B2 | Synthesis of coelenterazine | INTERNATIONAL PAPER COMPANY (US) | 2024-03-26 | — | — | US | disclosed |
| US-8883432-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140316137-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORP (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140206868-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2014-07-24 | — | — | US | disclosed |
| US-8772484-B2 | Process for producing benzo[f]quinoxaline compounds | JNC CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20140120538-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8642281-B2 | Coelenterazine analogues and coelenteramide analogues | JNC CORPORATION (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20120232272-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | JNC CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140120538-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | PREP 372/4885DRD2 2537/4885CA12 131/4885 |
| US-11939332-B2 | Synthesis of coelenterazine | ACHE, UROD, DDT | PREP 133/4885DRD2 1432/4885CA12 1056/4885 |
| US-20140206868-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | F5, METAP2, MTX2 | PREP 315/4885DRD2 732/4885CA12 636/4885 |
| US-20140316137-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | PREP 437/4885DRD2 2637/4885CA12 266/4885 |
| US-20240239803-A1 | SYNTHESIS OF COELENTERAZINE | ACHE, UROD, DDT | PREP 133/4885DRD2 1432/4885CA12 1056/4885 |
| US-20210070762-A1 | SYNTHESIS OF COELENTERAZINE | ACHE, UROD, DDT | PREP 133/4885DRD2 1432/4885CA12 1056/4885 |
| US-20120232272-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | F5, METAP2, MTX2 | PREP 315/4885DRD2 732/4885CA12 636/4885 |
| US-20110244481-A1 | COELENTERAZINE ANALOGUES AND COELENTERAMIDE ANALOGUES | CCKAR, SI, GLP1R | PREP 372/4885DRD2 2537/4885CA12 131/4885 |
| US-20260016473-A1 | REAGENT FOR DETECTING SARS-RELATED CORONAVIRUS | SARS1, CYP2F1, CYP7A1 | PREP 1566/4885DRD2 1667/4885CA12 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.